Drug Trial Radar · NCT05497635
A Study of STSA-1002 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Oct 14, 2022
Primary completion
Apr 6, 2023
Study completion Apr 6, 2023
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a Phase Ib, randomized, double-blind, placebo-controlled, multiple dose, dose escalation safety, tolerability,pharmacokinetic and pharmacodynamic study of STSA-1002 injection in healthy subjects. A total of 26 healthy subjects were enrolled in three dosage groups.
Conditions
- Healthy Subject
Interventions
STSA-1002 InjectionDrug
Intravenous injection
PlaceboDrug
Intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events、Clinically Significant Laboratory Abnormalities、Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.Time frame: Up to Study Day 56
- Maximum plasma concentration (Cmax)Time frame: From Day 0 to Day 56
- Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)Time frame: From Day 0 to Day 56
- Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: From Day 0 to Day 56
- Time of maximum concentration (Tmax)Time frame: From Day 0 to Day 56
- Elimination half-life (t1/2)Time frame: From Day 0 to Day 56
- Mean residence time (MRT)Time frame: From Day 0 to Day 56
- Clearance (CL)Time frame: From Day 0 to Day 56
- Apparent volume of distribution (Vz)Time frame: From Day 0 to Day 56
- Maximum Concentration of the Analyte in Plasma at steady state(Cmax, ss)Time frame: From Day 0 to Day 56
- Minimum Measured Concentration of the Analyte in Plasma at Steady State(Cmin, ss)Time frame: From Day 0 to Day 56
- Time-averaged concentration at steady state(Cav, ss)Time frame: From Day 0 to Day 56
- Area under the concentration curve from time 0 extrapolate to infinite time(AUCinf,ss)Time frame: From Day 0 to Day 56
- Degree of fluctuation(DF)Time frame: From Day 0 to Day 56
- Accumulation factorTime frame: From Day 0 to Day 56
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Shijitan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
The Second Affiliated Hospital Of Xingtai Medical College
Xingtai, Hebei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.